Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization
China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA:...
SHE: 300199
Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline
This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...
Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...
Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA
China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...
Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar
BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...
Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...
Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...
Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...
Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...
Hybio’s COVID-19 Nasal Spray HY3000 Gets FDA Clinical Trial Approval
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving tacit clinical trial approval from...
Hybio Pharma and CR Medicine Collaborate on Market Expansion
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...
Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...
Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...